Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety

Executive Summary

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.

You may also be interested in...



COMPASS Psilocybin Depression Data Excite Despite Safety Issues

The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.

Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News

The latest drug development news and highlights from our US FDA Performance Tracker.

Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s

Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel